#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Cancer has been a major threat to human health in recent years .
3-1	17-23	Cancer	abstract	new	coref	3-4[4_0]
3-2	24-27	has	_	_	_	_
3-3	28-32	been	_	_	_	_
3-4	33-34	a	abstract[4]	giv[4]	coref	5-13[0_4]
3-5	35-40	major	abstract[4]	giv[4]	_	_
3-6	41-47	threat	abstract[4]	giv[4]	_	_
3-7	48-50	to	abstract[4]	giv[4]	_	_
3-8	51-56	human	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-9	57-63	health	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-10	64-66	in	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-11	67-73	recent	abstract[4]|abstract[5]|time[6]	giv[4]|new[5]|new[6]	coref	4-2[7_6]
3-12	74-79	years	abstract[4]|abstract[5]|time[6]	giv[4]|new[5]|new[6]	_	_
3-13	80-81	.	_	_	_	_

#Text=In the past forty years , even though great efforts have been made , there is still much to be done before a safe therapy is achieved .
4-1	82-84	In	_	_	_	_
4-2	85-88	the	time[7]	giv[7]	_	_
4-3	89-93	past	time[7]	giv[7]	_	_
4-4	94-99	forty	time[7]	giv[7]	_	_
4-5	100-105	years	time[7]	giv[7]	_	_
4-6	106-107	,	_	_	_	_
4-7	108-112	even	_	_	_	_
4-8	113-119	though	_	_	_	_
4-9	120-125	great	abstract[8]	new[8]	_	_
4-10	126-133	efforts	abstract[8]	new[8]	_	_
4-11	134-138	have	_	_	_	_
4-12	139-143	been	_	_	_	_
4-13	144-148	made	_	_	_	_
4-14	149-150	,	_	_	_	_
4-15	151-156	there	_	_	_	_
4-16	157-159	is	_	_	_	_
4-17	160-165	still	_	_	_	_
4-18	166-170	much	_	_	_	_
4-19	171-173	to	_	_	_	_
4-20	174-176	be	_	_	_	_
4-21	177-181	done	_	_	_	_
4-22	182-188	before	_	_	_	_
4-23	189-190	a	event[9]	new[9]	coref	8-7[28_9]
4-24	191-195	safe	event[9]	new[9]	_	_
4-25	196-203	therapy	event[9]	new[9]	_	_
4-26	204-206	is	_	_	_	_
4-27	207-215	achieved	_	_	_	_
4-28	216-217	.	_	_	_	_

#Text=Currently , chemotherapy and radiotherapy are still the main therapeutic methods for cancer .
5-1	218-227	Currently	_	_	_	_
5-2	228-229	,	_	_	_	_
5-3	230-242	chemotherapy	abstract	new	_	_
5-4	243-246	and	_	_	_	_
5-5	247-259	radiotherapy	abstract	new	coref	5-7[12_0]
5-6	260-263	are	_	_	_	_
5-7	264-269	still	abstract[12]	giv[12]	_	_
5-8	270-273	the	abstract[12]	giv[12]	_	_
5-9	274-278	main	abstract[12]	giv[12]	_	_
5-10	279-290	therapeutic	abstract[12]	giv[12]	_	_
5-11	291-298	methods	abstract[12]	giv[12]	_	_
5-12	299-302	for	abstract[12]	giv[12]	_	_
5-13	303-309	cancer	abstract[12]|abstract	giv[12]|giv	coref	8-17
5-14	310-311	.	_	_	_	_

#Text=However , most of the anticancer drugs have toxic side effects .
6-1	312-319	However	_	_	_	_
6-2	320-321	,	_	_	_	_
6-3	322-326	most	substance[15]	new[15]	coref	7-8[19_15]
6-4	327-329	of	substance[15]	new[15]	_	_
6-5	330-333	the	substance[15]	new[15]	_	_
6-6	334-344	anticancer	abstract|substance[15]	new|new[15]	coref	26-16
6-7	345-350	drugs	substance[15]	new[15]	_	_
6-8	351-355	have	_	_	_	_
6-9	356-361	toxic	abstract[16]	new[16]	coref	7-13[21_16]
6-10	362-366	side	abstract[16]	new[16]	_	_
6-11	367-374	effects	abstract[16]	new[16]	_	_
6-12	375-376	.	_	_	_	_

#Text=Therefore , it is critical to develop novel anticancer drugs that have no toxic side effects on other tissues or organs in vivo , and only target the lesion area .
7-1	377-386	Therefore	_	_	_	_
7-2	387-388	,	_	_	_	_
7-3	389-391	it	event	new	cata	7-3[0_18]
7-4	392-394	is	_	_	_	_
7-5	395-403	critical	_	_	_	_
7-6	404-406	to	event[18]	new[18]	_	_
7-7	407-414	develop	event[18]|abstract	new[18]|new	coref|none	17-10[105_0]|7-7[0_189]
7-8	415-420	novel	event[18]|substance[19]	new[18]|giv[19]	coref	8-3[26_19]
7-9	421-431	anticancer	event[18]|substance[19]	new[18]|giv[19]	_	_
7-10	432-437	drugs	event[18]|substance[19]	new[18]|giv[19]	_	_
7-11	438-442	that	_	_	_	_
7-12	443-447	have	_	_	_	_
7-13	448-450	no	abstract[21]	giv[21]	_	_
7-14	451-456	toxic	abstract[21]	giv[21]	_	_
7-15	457-461	side	abstract|abstract[21]	new|giv[21]	_	_
7-16	462-469	effects	abstract[21]	giv[21]	_	_
7-17	470-472	on	abstract[21]	giv[21]	_	_
7-18	473-478	other	abstract[21]|object[22]	giv[21]|new[22]	_	_
7-19	479-486	tissues	abstract[21]|object[22]	giv[21]|new[22]	_	_
7-20	487-489	or	abstract[21]	giv[21]	_	_
7-21	490-496	organs	abstract[21]|abstract[23]	giv[21]|new[23]	_	_
7-22	497-499	in	abstract[21]|abstract[23]	giv[21]|new[23]	_	_
7-23	500-504	vivo	abstract[21]|abstract[23]	giv[21]|new[23]	_	_
7-24	505-506	,	_	_	_	_
7-25	507-510	and	_	_	_	_
7-26	511-515	only	_	_	_	_
7-27	516-522	target	_	_	_	_
7-28	523-526	the	abstract[25]	new[25]	coref	21-12[131_25]
7-29	527-533	lesion	abstract|abstract[25]	new|new[25]	_	_
7-30	534-538	area	abstract[25]	new[25]	_	_
7-31	539-540	.	_	_	_	_

#Text=Compared with traditional chemotherapeutic drugs , the nano-anticancer drug therapy has potential application prospects in curing cancer diseases .
8-1	541-549	Compared	_	_	_	_
8-2	550-554	with	_	_	_	_
8-3	555-566	traditional	substance[26]	giv[26]	coref	9-7[35_26]
8-4	567-583	chemotherapeutic	substance[26]	giv[26]	_	_
8-5	584-589	drugs	substance[26]	giv[26]	_	_
8-6	590-591	,	_	_	_	_
8-7	592-595	the	event[28]	giv[28]	_	_
8-8	596-611	nano-anticancer	event[28]	giv[28]	_	_
8-9	612-616	drug	substance|event[28]	new|giv[28]	coref	28-16
8-10	617-624	therapy	event[28]	giv[28]	_	_
8-11	625-628	has	_	_	_	_
8-12	629-638	potential	abstract[30]	new[30]	_	_
8-13	639-650	application	abstract|abstract[30]	new|new[30]	coref	28-13[187_0]
8-14	651-660	prospects	abstract[30]	new[30]	_	_
8-15	661-663	in	_	_	_	_
8-16	664-670	curing	_	_	_	_
8-17	671-677	cancer	abstract|abstract[32]	giv|new[32]	coref|coref	24-15[147_0]|24-15[147_0]
8-18	678-686	diseases	abstract[32]	new[32]	_	_
8-19	687-688	.	_	_	_	_

#Text=One of the major concerns about the nano-anticancer drugs is the drug-delivery vector .
9-1	689-692	One	abstract[33]	new[33]	coref	9-11[36_33]
9-2	693-695	of	abstract[33]	new[33]	_	_
9-3	696-699	the	abstract[33]|abstract[34]	new[33]|new[34]	_	_
9-4	700-705	major	abstract[33]|abstract[34]	new[33]|new[34]	_	_
9-5	706-714	concerns	abstract[33]|abstract[34]	new[33]|new[34]	_	_
9-6	715-720	about	abstract[33]|abstract[34]	new[33]|new[34]	_	_
9-7	721-724	the	abstract[33]|abstract[34]|substance[35]	new[33]|new[34]|giv[35]	coref	13-40[73_35]
9-8	725-740	nano-anticancer	abstract[33]|abstract[34]|substance[35]	new[33]|new[34]|giv[35]	_	_
9-9	741-746	drugs	abstract[33]|abstract[34]|substance[35]	new[33]|new[34]|giv[35]	_	_
9-10	747-749	is	_	_	_	_
9-11	750-753	the	abstract[36]	giv[36]	coref	10-1[38_36]
9-12	754-767	drug-delivery	abstract[36]	giv[36]	_	_
9-13	768-774	vector	abstract[36]	giv[36]	_	_
9-14	775-776	.	_	_	_	_

#Text=The ideal delivery vector should possess such characteristics as a high drug-loading capacity , low immunogenicity , low toxicity , better shelf-life , and water solubility , and it should have the potential to be further modified .
10-1	777-780	The	abstract[38]	giv[38]	ana	10-29[0_38]
10-2	781-786	ideal	abstract[38]	giv[38]	_	_
10-3	787-795	delivery	abstract|abstract[38]	new|giv[38]	coref	12-12
10-4	796-802	vector	abstract[38]	giv[38]	_	_
10-5	803-809	should	_	_	_	_
10-6	810-817	possess	_	_	_	_
10-7	818-822	such	abstract[39]	new[39]	_	_
10-8	823-838	characteristics	abstract[39]	new[39]	_	_
10-9	839-841	as	abstract[39]	new[39]	_	_
10-10	842-843	a	abstract[39]	new[39]	_	_
10-11	844-848	high	abstract[39]	new[39]	_	_
10-12	849-861	drug-loading	abstract[39]|substance	new[39]|new	_	_
10-13	862-870	capacity	abstract[39]	new[39]	_	_
10-14	871-872	,	abstract[39]	new[39]	_	_
10-15	873-876	low	abstract[39]	new[39]	_	_
10-16	877-891	immunogenicity	abstract[39]	new[39]	_	_
10-17	892-893	,	abstract[39]	new[39]	_	_
10-18	894-897	low	abstract[39]	new[39]	_	_
10-19	898-906	toxicity	abstract[39]	new[39]	_	_
10-20	907-908	,	abstract[39]	new[39]	_	_
10-21	909-915	better	abstract[39]	new[39]	_	_
10-22	916-926	shelf-life	abstract[39]	new[39]	_	_
10-23	927-928	,	abstract[39]	new[39]	_	_
10-24	929-932	and	abstract[39]	new[39]	_	_
10-25	933-938	water	abstract[39]|substance	new[39]|new	_	_
10-26	939-949	solubility	abstract[39]	new[39]	_	_
10-27	950-951	,	_	_	_	_
10-28	952-955	and	_	_	_	_
10-29	956-958	it	abstract	giv	coref	29-35[200_0]
10-30	959-965	should	_	_	_	_
10-31	966-970	have	_	_	_	_
10-32	971-974	the	abstract[43]	new[43]	_	_
10-33	975-984	potential	abstract[43]	new[43]	_	_
10-34	985-987	to	_	_	_	_
10-35	988-990	be	_	_	_	_
10-36	991-998	further	_	_	_	_
10-37	999-1007	modified	_	_	_	_
10-38	1008-1009	.	_	_	_	_

#Text=Synthetic polymers , such as , chitosan , polyetherimide ( PEI ) , poly(lactic-co-glycolic acid ) ( PLGA ) , polyamidoamine ( PAMAM ) , and poly-l-lactic acid ( PLA ) have been widely used in gene- and drug-delivery systems .
11-1	1010-1019	Synthetic	substance[44]	new[44]	_	_
11-2	1020-1028	polymers	substance[44]	new[44]	_	_
11-3	1029-1030	,	substance[44]	new[44]	_	_
11-4	1031-1035	such	substance[44]	new[44]	_	_
11-5	1036-1038	as	substance[44]	new[44]	_	_
11-6	1039-1040	,	substance[44]	new[44]	_	_
11-7	1041-1049	chitosan	substance[44]|substance	new[44]|new	_	_
11-8	1050-1051	,	_	_	_	_
11-9	1052-1066	polyetherimide	substance	new	appos	11-14[48_0]
11-10	1067-1068	(	_	_	_	_
11-11	1069-1072	PEI	person	new	_	_
11-12	1073-1074	)	_	_	_	_
11-13	1075-1076	,	_	_	_	_
11-14	1077-1100	poly(lactic-co-glycolic	substance[48]	giv[48]	coref	11-27[51_48]
11-15	1101-1105	acid	substance[48]	giv[48]	_	_
11-16	1106-1107	)	_	_	_	_
11-17	1108-1109	(	_	_	_	_
11-18	1110-1114	PLGA	_	_	_	_
11-19	1115-1116	)	_	_	_	_
11-20	1117-1118	,	_	_	_	_
11-21	1119-1133	polyamidoamine	substance	new	appos	11-23
11-22	1134-1135	(	_	_	_	_
11-23	1136-1141	PAMAM	substance	giv	_	_
11-24	1142-1143	)	_	_	_	_
11-25	1144-1145	,	_	_	_	_
11-26	1146-1149	and	_	_	_	_
11-27	1150-1163	poly-l-lactic	substance[51]	giv[51]	_	_
11-28	1164-1168	acid	substance[51]	giv[51]	_	_
11-29	1169-1170	(	_	_	_	_
11-30	1171-1174	PLA	abstract	new	_	_
11-31	1175-1176	)	_	_	_	_
11-32	1177-1181	have	_	_	_	_
11-33	1182-1186	been	_	_	_	_
11-34	1187-1193	widely	_	_	_	_
11-35	1194-1198	used	_	_	_	_
11-36	1199-1201	in	_	_	_	_
11-37	1202-1207	gene-	abstract|abstract[54]	new|new[54]	_	_
11-38	1208-1211	and	abstract[54]	new[54]	_	_
11-39	1212-1225	drug-delivery	abstract[54]	new[54]	_	_
11-40	1226-1233	systems	abstract[54]	new[54]	_	_
11-41	1234-1235	.	_	_	_	_

#Text=However , stability of sustained-release formulations in aqueous solution , long delivery times , and low delivery efficiency are only a small part of the challenges highlighted by researchers .
12-1	1236-1243	However	_	_	_	_
12-2	1244-1245	,	_	_	_	_
12-3	1246-1255	stability	abstract[55]	new[55]	_	_
12-4	1256-1258	of	abstract[55]	new[55]	_	_
12-5	1259-1276	sustained-release	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-6	1277-1289	formulations	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-7	1290-1292	in	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-8	1293-1300	aqueous	abstract[55]|substance[56]|substance[57]	new[55]|new[56]|new[57]	_	_
12-9	1301-1309	solution	abstract[55]|substance[56]|substance[57]	new[55]|new[56]|new[57]	_	_
12-10	1310-1311	,	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-11	1312-1316	long	abstract[55]|substance[56]|time[59]	new[55]|new[56]|new[59]	_	_
12-12	1317-1325	delivery	abstract[55]|substance[56]|abstract|time[59]	new[55]|new[56]|giv|new[59]	coref	12-17
12-13	1326-1331	times	abstract[55]|substance[56]|time[59]	new[55]|new[56]|new[59]	_	_
12-14	1332-1333	,	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-15	1334-1337	and	abstract[55]|substance[56]	new[55]|new[56]	_	_
12-16	1338-1341	low	abstract[55]|substance[56]|abstract[61]	new[55]|new[56]|new[61]	_	_
12-17	1342-1350	delivery	abstract[55]|substance[56]|abstract|abstract[61]	new[55]|new[56]|giv|new[61]	coref	15-12[90_0]
12-18	1351-1361	efficiency	abstract[55]|substance[56]|abstract[61]	new[55]|new[56]|new[61]	_	_
12-19	1362-1365	are	_	_	_	_
12-20	1366-1370	only	_	_	_	_
12-21	1371-1372	a	_	_	_	_
12-22	1373-1378	small	_	_	_	_
12-23	1379-1383	part	_	_	_	_
12-24	1384-1386	of	_	_	_	_
12-25	1387-1390	the	abstract[62]	new[62]	_	_
12-26	1391-1401	challenges	abstract[62]	new[62]	_	_
12-27	1402-1413	highlighted	_	_	_	_
12-28	1414-1416	by	_	_	_	_
12-29	1417-1428	researchers	person	new	_	_
12-30	1429-1430	.	_	_	_	_

#Text=Dendrigraft poly-l-lysines ( DGL ) have emerged as a new kind of synthetic polymer consisting of lysine and have been employed as drug- or gene-delivery carriers , due to their biodegradability and rich external amino groups that can encapsulate drugs by the emulsion crosslinking method or plasmid DNA through electric interactions .
13-1	1431-1442	Dendrigraft	abstract[64]	new[64]	ana	13-30[0_64]
13-2	1443-1457	poly-l-lysines	abstract[64]	new[64]	_	_
13-3	1458-1459	(	_	_	_	_
13-4	1460-1463	DGL	object	new	coref	22-10[136_0]
13-5	1464-1465	)	_	_	_	_
13-6	1466-1470	have	_	_	_	_
13-7	1471-1478	emerged	_	_	_	_
13-8	1479-1481	as	_	_	_	_
13-9	1482-1483	a	_	_	_	_
13-10	1484-1487	new	_	_	_	_
13-11	1488-1492	kind	substance[66]	new[66]	_	_
13-12	1493-1495	of	substance[66]	new[66]	_	_
13-13	1496-1505	synthetic	substance[66]	new[66]	_	_
13-14	1506-1513	polymer	substance[66]	new[66]	_	_
13-15	1514-1524	consisting	_	_	_	_
13-16	1525-1527	of	_	_	_	_
13-17	1528-1534	lysine	substance	new	_	_
13-18	1535-1538	and	_	_	_	_
13-19	1539-1543	have	_	_	_	_
13-20	1544-1548	been	_	_	_	_
13-21	1549-1557	employed	_	_	_	_
13-22	1558-1560	as	_	_	_	_
13-23	1561-1566	drug-	_	_	_	_
13-24	1567-1569	or	_	_	_	_
13-25	1570-1583	gene-delivery	abstract	new	_	_
13-26	1584-1592	carriers	_	_	_	_
13-27	1593-1594	,	_	_	_	_
13-28	1595-1598	due	_	_	_	_
13-29	1599-1601	to	_	_	_	_
13-30	1602-1607	their	abstract|person[72]	giv|new[72]	ana|ana	14-2|14-2
13-31	1608-1624	biodegradability	substance|person[72]	new|new[72]	coref	14-2[80_0]
13-32	1625-1628	and	person[72]	new[72]	_	_
13-33	1629-1633	rich	person[72]	new[72]	_	_
13-34	1634-1642	external	person[72]	new[72]	_	_
13-35	1643-1648	amino	object|person[72]	new|new[72]	_	_
13-36	1649-1655	groups	person[72]	new[72]	_	_
13-37	1656-1660	that	_	_	_	_
13-38	1661-1664	can	_	_	_	_
13-39	1665-1676	encapsulate	_	_	_	_
13-40	1677-1682	drugs	substance[73]	giv[73]	coref	15-15[91_73]
13-41	1683-1685	by	substance[73]	giv[73]	_	_
13-42	1686-1689	the	substance[73]|abstract[76]	giv[73]|new[76]	_	_
13-43	1690-1698	emulsion	substance[73]|event|abstract[76]	giv[73]|new|new[76]	_	_
13-44	1699-1711	crosslinking	substance[73]|event|abstract[76]	giv[73]|new|new[76]	_	_
13-45	1712-1718	method	substance[73]|abstract[76]	giv[73]|new[76]	_	_
13-46	1719-1721	or	substance[73]	giv[73]	_	_
13-47	1722-1729	plasmid	substance[73]|object[77]	giv[73]|new[77]	_	_
13-48	1730-1733	DNA	substance[73]|object[77]	giv[73]|new[77]	_	_
13-49	1734-1741	through	_	_	_	_
13-50	1742-1750	electric	abstract[78]	new[78]	_	_
13-51	1751-1763	interactions	abstract[78]	new[78]	_	_
13-52	1764-1765	.	_	_	_	_

#Text=Besides their biodegradability , they can also be modified with targeting ligands and polyethylene glycol ( PEG ) , thereby rendering vectors with targeting properties and long circulation .
14-1	1766-1773	Besides	_	_	_	_
14-2	1774-1779	their	person|substance[80]	giv|giv[80]	ana|ana	14-5|14-5
14-3	1780-1796	biodegradability	substance[80]	giv[80]	_	_
14-4	1797-1798	,	_	_	_	_
14-5	1799-1803	they	person	giv	_	_
14-6	1804-1807	can	_	_	_	_
14-7	1808-1812	also	_	_	_	_
14-8	1813-1815	be	_	_	_	_
14-9	1816-1824	modified	_	_	_	_
14-10	1825-1829	with	_	_	_	_
14-11	1830-1839	targeting	_	_	_	_
14-12	1840-1847	ligands	substance	new	_	_
14-13	1848-1851	and	_	_	_	_
14-14	1852-1864	polyethylene	substance|substance[84]	new|new[84]	_	_
14-15	1865-1871	glycol	substance[84]	new[84]	_	_
14-16	1872-1873	(	_	_	_	_
14-17	1874-1877	PEG	object	new	_	_
14-18	1878-1879	)	_	_	_	_
14-19	1880-1881	,	_	_	_	_
14-20	1882-1889	thereby	_	_	_	_
14-21	1890-1899	rendering	_	_	_	_
14-22	1900-1907	vectors	object[86]	new[86]	_	_
14-23	1908-1912	with	object[86]	new[86]	_	_
14-24	1913-1922	targeting	object[86]|abstract[87]	new[86]|new[87]	_	_
14-25	1923-1933	properties	object[86]|abstract[87]	new[86]|new[87]	_	_
14-26	1934-1937	and	object[86]	new[86]	_	_
14-27	1938-1942	long	object[86]|abstract[88]	new[86]|new[88]	_	_
14-28	1943-1954	circulation	object[86]|abstract[88]	new[86]|new[88]	_	_
14-29	1955-1956	.	_	_	_	_

#Text=As yet , there are only a few ways available for targeted delivery of anticancer drugs .
15-1	1957-1959	As	_	_	_	_
15-2	1960-1963	yet	_	_	_	_
15-3	1964-1965	,	_	_	_	_
15-4	1966-1971	there	_	_	_	_
15-5	1972-1975	are	_	_	_	_
15-6	1976-1980	only	_	_	_	_
15-7	1981-1982	a	abstract[89]	new[89]	_	_
15-8	1983-1986	few	abstract[89]	new[89]	_	_
15-9	1987-1991	ways	abstract[89]	new[89]	_	_
15-10	1992-2001	available	abstract[89]	new[89]	_	_
15-11	2002-2005	for	_	_	_	_
15-12	2006-2014	targeted	abstract[90]	giv[90]	_	_
15-13	2015-2023	delivery	abstract[90]	giv[90]	_	_
15-14	2024-2026	of	abstract[90]	giv[90]	_	_
15-15	2027-2037	anticancer	abstract[90]|substance[91]	giv[90]|giv[91]	coref	17-10[104_91]
15-16	2038-2043	drugs	abstract[90]|substance[91]	giv[90]|giv[91]	_	_
15-17	2044-2045	.	_	_	_	_

#Text=Recently , a report showed that VAR2CSA , which is exposed on the membrane of Plasmodium falciparum infected red blood cells ( iRBC ) , could bind to 90 % of tumors , which was verified by running immunohistochemistry on a tumor-tissue array .
16-1	2046-2054	Recently	_	_	_	_
16-2	2055-2056	,	_	_	_	_
16-3	2057-2058	a	abstract[92]	new[92]	_	_
16-4	2059-2065	report	abstract[92]	new[92]	_	_
16-5	2066-2072	showed	_	_	_	_
16-6	2073-2077	that	_	_	_	_
16-7	2078-2085	VAR2CSA	abstract	new	coref	17-3
16-8	2086-2087	,	_	_	_	_
16-9	2088-2093	which	_	_	_	_
16-10	2094-2096	is	_	_	_	_
16-11	2097-2104	exposed	_	_	_	_
16-12	2105-2107	on	_	_	_	_
16-13	2108-2111	the	place[94]	new[94]	_	_
16-14	2112-2120	membrane	place[94]	new[94]	_	_
16-15	2121-2123	of	place[94]	new[94]	_	_
16-16	2124-2134	Plasmodium	place[94]|substance|object[96]	new[94]|new|new[96]	coref|coref	18-1[107_96]|18-1[107_96]
16-17	2135-2145	falciparum	place[94]|object[96]	new[94]|new[96]	_	_
16-18	2146-2154	infected	place[94]|object[96]|object[97]	new[94]|new[96]|new[97]	appos	16-23[0_97]
16-19	2155-2158	red	place[94]|object[96]|object[97]	new[94]|new[96]|new[97]	_	_
16-20	2159-2164	blood	place[94]|object[96]|object[97]	new[94]|new[96]|new[97]	_	_
16-21	2165-2170	cells	place[94]|object[96]|object[97]	new[94]|new[96]|new[97]	_	_
16-22	2171-2172	(	_	_	_	_
16-23	2173-2177	iRBC	object	giv	coref	19-9
16-24	2178-2179	)	_	_	_	_
16-25	2180-2181	,	_	_	_	_
16-26	2182-2187	could	_	_	_	_
16-27	2188-2192	bind	_	_	_	_
16-28	2193-2195	to	_	_	_	_
16-29	2196-2198	90	quantity[99]	new[99]	_	_
16-30	2199-2200	%	quantity[99]	new[99]	_	_
16-31	2201-2203	of	quantity[99]	new[99]	_	_
16-32	2204-2210	tumors	quantity[99]|object	new[99]|new	_	_
16-33	2211-2212	,	_	_	_	_
16-34	2213-2218	which	_	_	_	_
16-35	2219-2222	was	_	_	_	_
16-36	2223-2231	verified	_	_	_	_
16-37	2232-2234	by	_	_	_	_
16-38	2235-2242	running	_	_	_	_
16-39	2243-2263	immunohistochemistry	abstract	new	_	_
16-40	2264-2266	on	_	_	_	_
16-41	2267-2268	a	object[102]	new[102]	_	_
16-42	2269-2281	tumor-tissue	object[102]	new[102]	_	_
16-43	2282-2287	array	object[102]	new[102]	_	_
16-44	2288-2289	.	_	_	_	_

#Text=Therefore , VAR2CSA is becoming an attractive target for anticancer drugs ’ development .
17-1	2290-2299	Therefore	_	_	_	_
17-2	2300-2301	,	_	_	_	_
17-3	2302-2309	VAR2CSA	substance	giv	coref	19-31
17-4	2310-2312	is	_	_	_	_
17-5	2313-2321	becoming	_	_	_	_
17-6	2322-2324	an	_	_	_	_
17-7	2325-2335	attractive	_	_	_	_
17-8	2336-2342	target	_	_	_	_
17-9	2343-2346	for	_	_	_	_
17-10	2347-2357	anticancer	substance[104]|abstract[105]	giv[104]|new[105]	coref|coref	28-16[189_105]|28-16[189_105]
17-11	2358-2363	drugs	substance[104]|abstract[105]	giv[104]|new[105]	_	_
17-12	2364-2365	’	substance[104]|abstract[105]	giv[104]|new[105]	_	_
17-13	2366-2377	development	abstract[105]	new[105]	_	_
17-14	2378-2379	.	_	_	_	_

#Text=P. falciparum
18-1	2380-2382	P.	place|object[107]	new|giv[107]	_	_
18-2	2383-2393	falciparum	object[107]	giv[107]	_	_

#Text=infection during pregnancy results in the sequestration of iRBC in the placenta by adhering to a distinct type of chondroitin sulfate A ( CSA ) exclusively expressed on trophoblast via VAR2CSA .
19-1	2394-2403	infection	event[108]	new[108]	_	_
19-2	2404-2410	during	event[108]	new[108]	_	_
19-3	2411-2420	pregnancy	event[108]|event|abstract[110]	new[108]|new|new[110]	_	_
19-4	2421-2428	results	event[108]|abstract[110]	new[108]|new[110]	_	_
19-5	2429-2431	in	event[108]|abstract[110]	new[108]|new[110]	_	_
19-6	2432-2435	the	event[108]|abstract[110]|abstract[111]	new[108]|new[110]|new[111]	_	_
19-7	2436-2449	sequestration	event[108]|abstract[110]|abstract[111]	new[108]|new[110]|new[111]	_	_
19-8	2450-2452	of	event[108]|abstract[110]|abstract[111]	new[108]|new[110]|new[111]	_	_
19-9	2453-2457	iRBC	event[108]|abstract[110]|abstract[111]|substance	new[108]|new[110]|new[111]|giv	coref	24-42[158_0]
19-10	2458-2460	in	event[108]|abstract[110]|abstract[111]	new[108]|new[110]|new[111]	_	_
19-11	2461-2464	the	event[108]|abstract[110]|abstract[111]|place[113]	new[108]|new[110]|new[111]|new[113]	coref	21-5[0_113]
19-12	2465-2473	placenta	event[108]|abstract[110]|abstract[111]|place[113]	new[108]|new[110]|new[111]|new[113]	_	_
19-13	2474-2476	by	_	_	_	_
19-14	2477-2485	adhering	_	_	_	_
19-15	2486-2488	to	_	_	_	_
19-16	2489-2490	a	abstract[114]	new[114]	_	_
19-17	2491-2499	distinct	abstract[114]	new[114]	_	_
19-18	2500-2504	type	abstract[114]	new[114]	_	_
19-19	2505-2507	of	abstract[114]	new[114]	_	_
19-20	2508-2519	chondroitin	abstract[114]|person	new[114]|new	_	_
19-21	2520-2527	sulfate	abstract[114]|person	new[114]|new	_	_
19-22	2528-2529	A	abstract[114]	new[114]	_	_
19-23	2530-2531	(	_	_	_	_
19-24	2532-2535	CSA	place	new	coref	20-12
19-25	2536-2537	)	_	_	_	_
19-26	2538-2549	exclusively	_	_	_	_
19-27	2550-2559	expressed	_	_	_	_
19-28	2560-2562	on	_	_	_	_
19-29	2563-2574	trophoblast	place[118]	new[118]	_	_
19-30	2575-2578	via	place[118]	new[118]	_	_
19-31	2579-2586	VAR2CSA	place[118]|object	new[118]|giv	coref	20-5
19-32	2587-2588	.	_	_	_	_

#Text=Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined .
20-1	2589-2594	Short	place[120]	new[120]	_	_
20-2	2595-2605	continuous	place[120]	new[120]	_	_
20-3	2606-2613	regions	place[120]	new[120]	_	_
20-4	2614-2616	of	place[120]	new[120]	_	_
20-5	2617-2624	VAR2CSA	place[120]|abstract	new[120]|giv	coref	21-13
20-6	2625-2629	with	place[120]	new[120]	_	_
20-7	2630-2638	affinity	place[120]|abstract[122]	new[120]|new[122]	_	_
20-8	2639-2642	for	place[120]|abstract[122]	new[120]|new[122]	_	_
20-9	2643-2651	multiple	place[120]|abstract[122]|abstract[123]	new[120]|new[122]|new[123]	_	_
20-10	2652-2657	types	place[120]|abstract[122]|abstract[123]	new[120]|new[122]|new[123]	_	_
20-11	2658-2660	of	place[120]|abstract[122]|abstract[123]	new[120]|new[122]|new[123]	_	_
20-12	2661-2664	CSA	place[120]|abstract[122]|abstract[123]|abstract	new[120]|new[122]|new[123]|giv	_	_
20-13	2665-2669	were	_	_	_	_
20-14	2670-2677	defined	_	_	_	_
20-15	2678-2679	.	_	_	_	_

#Text=A 28 amino acids placenta CSA-binding peptide ( plCSA-BP ) from the VAR2CSA region was recently tested as a guide peptide for targeted delivery of doxorubicin to choriocarcinoma .
21-1	2680-2681	A	person[125]|abstract[128]	new[125]|new[128]	_	_
21-2	2682-2684	28	person[125]|abstract[128]	new[125]|new[128]	_	_
21-3	2685-2690	amino	person[125]|abstract[128]	new[125]|new[128]	_	_
21-4	2691-2696	acids	person[125]|abstract[128]	new[125]|new[128]	_	_
21-5	2697-2705	placenta	place|abstract[128]	giv|new[128]	_	_
21-6	2706-2717	CSA-binding	abstract|abstract[128]	new|new[128]	_	_
21-7	2718-2725	peptide	abstract[128]	new[128]	_	_
21-8	2726-2727	(	_	_	_	_
21-9	2728-2736	plCSA-BP	object	new	coref	29-27
21-10	2737-2738	)	_	_	_	_
21-11	2739-2743	from	_	_	_	_
21-12	2744-2747	the	abstract[131]	giv[131]	_	_
21-13	2748-2755	VAR2CSA	place|abstract[131]	giv|giv[131]	_	_
21-14	2756-2762	region	abstract[131]	giv[131]	_	_
21-15	2763-2766	was	_	_	_	_
21-16	2767-2775	recently	_	_	_	_
21-17	2776-2782	tested	_	_	_	_
21-18	2783-2785	as	_	_	_	_
21-19	2786-2787	a	_	_	_	_
21-20	2788-2793	guide	_	_	_	_
21-21	2794-2801	peptide	_	_	_	_
21-22	2802-2805	for	_	_	_	_
21-23	2806-2814	targeted	abstract[132]	new[132]	coref	29-13[0_132]
21-24	2815-2823	delivery	abstract[132]	new[132]	_	_
21-25	2824-2826	of	abstract[132]	new[132]	_	_
21-26	2827-2838	doxorubicin	abstract[132]|object	new[132]|new	_	_
21-27	2839-2841	to	abstract[132]	new[132]	_	_
21-28	2842-2857	choriocarcinoma	abstract[132]|abstract	new[132]|new	ana	22-4
21-29	2858-2859	.	_	_	_	_

#Text=However , whether it could be used to modify the DGL and its bioactivity after the modification was not evaluated .
22-1	2860-2867	However	_	_	_	_
22-2	2868-2869	,	_	_	_	_
22-3	2870-2877	whether	_	_	_	_
22-4	2878-2880	it	abstract	giv	ana	22-13
22-5	2881-2886	could	_	_	_	_
22-6	2887-2889	be	_	_	_	_
22-7	2890-2894	used	_	_	_	_
22-8	2895-2897	to	_	_	_	_
22-9	2898-2904	modify	_	_	_	_
22-10	2905-2908	the	object[136]	giv[136]	coref	29-36[0_136]
22-11	2909-2912	DGL	object[136]	giv[136]	_	_
22-12	2913-2916	and	_	_	_	_
22-13	2917-2920	its	abstract|abstract[138]	giv|new[138]	coref|coref	25-12|25-12
22-14	2921-2932	bioactivity	abstract[138]	new[138]	_	_
22-15	2933-2938	after	_	_	_	_
22-16	2939-2942	the	event[139]	new[139]	_	_
22-17	2943-2955	modification	event[139]	new[139]	_	_
22-18	2956-2959	was	_	_	_	_
22-19	2960-2963	not	_	_	_	_
22-20	2964-2973	evaluated	_	_	_	_
22-21	2974-2975	.	_	_	_	_

#Text=The immunosuppressive , antimalarial , and pro-cytotoxic bacterial prodigiosin was recently described as a potent antimetastatic and anticancer agent .
23-1	2976-2979	The	substance[141]	new[141]	ana	24-1[0_141]
23-2	2980-2997	immunosuppressive	substance[141]	new[141]	_	_
23-3	2998-2999	,	substance[141]	new[141]	_	_
23-4	3000-3012	antimalarial	substance[141]	new[141]	_	_
23-5	3013-3014	,	substance[141]	new[141]	_	_
23-6	3015-3018	and	substance[141]	new[141]	_	_
23-7	3019-3032	pro-cytotoxic	substance[141]	new[141]	_	_
23-8	3033-3042	bacterial	substance|substance[141]	new|new[141]	_	_
23-9	3043-3054	prodigiosin	substance[141]	new[141]	_	_
23-10	3055-3058	was	_	_	_	_
23-11	3059-3067	recently	_	_	_	_
23-12	3068-3077	described	_	_	_	_
23-13	3078-3080	as	_	_	_	_
23-14	3081-3082	a	_	_	_	_
23-15	3083-3089	potent	_	_	_	_
23-16	3090-3104	antimetastatic	_	_	_	_
23-17	3105-3108	and	_	_	_	_
23-18	3109-3119	anticancer	_	_	_	_
23-19	3120-3125	agent	_	_	_	_
23-20	3126-3127	.	_	_	_	_

#Text=It can induce apoptosis in a wide range of cancer cell lines , including hematopoietic cancer , breast cancer , gastric cancer , colon cancer , lung cancer , and rat hepatocellular carcinoma cell lines , with no marked toxicity in nonmalignant cells .
24-1	3128-3130	It	substance	giv	coref	25-3
24-2	3131-3134	can	_	_	_	_
24-3	3135-3141	induce	_	_	_	_
24-4	3142-3151	apoptosis	abstract[143]	new[143]	coref	26-6[163_143]
24-5	3152-3154	in	abstract[143]	new[143]	_	_
24-6	3155-3156	a	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-7	3157-3161	wide	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-8	3162-3167	range	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-9	3168-3170	of	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-10	3171-3177	cancer	abstract[143]|abstract[144]|object[146]	new[143]|new[144]|new[146]	_	_
24-11	3178-3182	cell	abstract[143]|abstract[144]|place|object[146]	new[143]|new[144]|new|new[146]	coref	24-34
24-12	3183-3188	lines	abstract[143]|abstract[144]|object[146]	new[143]|new[144]|new[146]	_	_
24-13	3189-3190	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-14	3191-3200	including	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-15	3201-3214	hematopoietic	abstract[143]|abstract[144]|abstract[147]	new[143]|new[144]|giv[147]	coref	24-18[148_147]
24-16	3215-3221	cancer	abstract[143]|abstract[144]|abstract[147]	new[143]|new[144]|giv[147]	_	_
24-17	3222-3223	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-18	3224-3230	breast	abstract[143]|abstract[144]|abstract[148]	new[143]|new[144]|giv[148]	coref	24-21[150_148]
24-19	3231-3237	cancer	abstract[143]|abstract[144]|abstract[148]	new[143]|new[144]|giv[148]	_	_
24-20	3238-3239	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-21	3240-3247	gastric	abstract[143]|abstract[144]|abstract|abstract[150]	new[143]|new[144]|new|giv[150]	coref|coref	24-24[151_150]|24-24[151_150]
24-22	3248-3254	cancer	abstract[143]|abstract[144]|abstract[150]	new[143]|new[144]|giv[150]	_	_
24-23	3255-3256	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-24	3257-3262	colon	abstract[143]|abstract[144]|abstract[151]	new[143]|new[144]|giv[151]	coref	24-27[152_151]
24-25	3263-3269	cancer	abstract[143]|abstract[144]|abstract[151]	new[143]|new[144]|giv[151]	_	_
24-26	3270-3271	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-27	3272-3276	lung	abstract[143]|abstract[144]|abstract[152]	new[143]|new[144]|giv[152]	coref	32-30[0_152]
24-28	3277-3283	cancer	abstract[143]|abstract[144]|abstract[152]	new[143]|new[144]|giv[152]	_	_
24-29	3284-3285	,	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-30	3286-3289	and	abstract[143]|abstract[144]	new[143]|new[144]	_	_
24-31	3290-3293	rat	abstract[143]|abstract[144]|object[156]	new[143]|new[144]|new[156]	_	_
24-32	3294-3308	hepatocellular	abstract[143]|abstract[144]|abstract|object[156]	new[143]|new[144]|new|new[156]	_	_
24-33	3309-3318	carcinoma	abstract[143]|abstract[144]|abstract|object[156]	new[143]|new[144]|new|new[156]	_	_
24-34	3319-3323	cell	abstract[143]|abstract[144]|place|object[156]	new[143]|new[144]|giv|new[156]	coref	30-23
24-35	3324-3329	lines	abstract[143]|abstract[144]|object[156]	new[143]|new[144]|new[156]	_	_
24-36	3330-3331	,	abstract[143]|abstract[144]|object[156]	new[143]|new[144]|new[156]	_	_
24-37	3332-3336	with	abstract[143]|abstract[144]|object[156]	new[143]|new[144]|new[156]	_	_
24-38	3337-3339	no	abstract[143]|abstract[144]|object[156]|abstract[157]	new[143]|new[144]|new[156]|new[157]	_	_
24-39	3340-3346	marked	abstract[143]|abstract[144]|object[156]|abstract[157]	new[143]|new[144]|new[156]|new[157]	_	_
24-40	3347-3355	toxicity	abstract[143]|abstract[144]|object[156]|abstract[157]	new[143]|new[144]|new[156]|new[157]	_	_
24-41	3356-3358	in	abstract[143]|abstract[144]|object[156]|abstract[157]	new[143]|new[144]|new[156]|new[157]	_	_
24-42	3359-3371	nonmalignant	abstract[143]|abstract[144]|object[156]|abstract[157]|object[158]	new[143]|new[144]|new[156]|new[157]|giv[158]	coref	26-8[165_158]
24-43	3372-3377	cells	abstract[143]|abstract[144]|object[156]|abstract[157]|object[158]	new[143]|new[144]|new[156]|new[157]|giv[158]	_	_
24-44	3378-3379	.	_	_	_	_

#Text=However , prodigiosin has not been reported for the treatment of choriocarcinoma yet .
25-1	3380-3387	However	_	_	_	_
25-2	3388-3389	,	_	_	_	_
25-3	3390-3401	prodigiosin	substance	giv	ana	26-1
25-4	3402-3405	has	_	_	_	_
25-5	3406-3409	not	_	_	_	_
25-6	3410-3414	been	_	_	_	_
25-7	3415-3423	reported	_	_	_	_
25-8	3424-3427	for	_	_	_	_
25-9	3428-3431	the	abstract[160]	new[160]	_	_
25-10	3432-3441	treatment	abstract[160]	new[160]	_	_
25-11	3442-3444	of	abstract[160]	new[160]	_	_
25-12	3445-3460	choriocarcinoma	abstract[160]|abstract	new[160]|giv	coref	30-22
25-13	3461-3464	yet	_	_	_	_
25-14	3465-3466	.	_	_	_	_

#Text=It is selective in promoting apoptosis of malignant tumor cells , rendering prodigiosin a promising anticancer agent .
26-1	3467-3469	It	substance	giv	coref	26-13
26-2	3470-3472	is	_	_	_	_
26-3	3473-3482	selective	_	_	_	_
26-4	3483-3485	in	_	_	_	_
26-5	3486-3495	promoting	_	_	_	_
26-6	3496-3505	apoptosis	abstract[163]	giv[163]	_	_
26-7	3506-3508	of	abstract[163]	giv[163]	_	_
26-8	3509-3518	malignant	abstract[163]|object[165]	giv[163]|giv[165]	_	_
26-9	3519-3524	tumor	abstract[163]|abstract|object[165]	giv[163]|new|giv[165]	coref	30-30
26-10	3525-3530	cells	abstract[163]|object[165]	giv[163]|giv[165]	_	_
26-11	3531-3532	,	_	_	_	_
26-12	3533-3542	rendering	_	_	_	_
26-13	3543-3554	prodigiosin	substance	giv	coref	27-5
26-14	3555-3556	a	person[168]	new[168]	_	_
26-15	3557-3566	promising	person[168]	new[168]	_	_
26-16	3567-3577	anticancer	abstract|person[168]	giv|new[168]	_	_
26-17	3578-3583	agent	person[168]	new[168]	_	_
26-18	3584-3585	.	_	_	_	_

#Text=The antitumor mechanism of prodigiosin is still unclear , especially in regard to newly acquired prodigiosin produced by a small number of microorganisms , including Serratia marcescens and other bacteria , such as Streptomyces griseoviridis , Serratia spp. , Zooshikellarubidus , Vibrio sp . , Actinomycetes , and Hahella chejuensis .
27-1	3586-3589	The	abstract[169]	new[169]	_	_
27-2	3590-3599	antitumor	abstract[169]	new[169]	_	_
27-3	3600-3609	mechanism	abstract[169]	new[169]	_	_
27-4	3610-3612	of	abstract[169]	new[169]	_	_
27-5	3613-3624	prodigiosin	abstract[169]|substance	new[169]|giv	coref	27-14[172_0]
27-6	3625-3627	is	_	_	_	_
27-7	3628-3633	still	_	_	_	_
27-8	3634-3641	unclear	_	_	_	_
27-9	3642-3643	,	_	_	_	_
27-10	3644-3654	especially	abstract[171]	new[171]	_	_
27-11	3655-3657	in	abstract[171]	new[171]	_	_
27-12	3658-3664	regard	abstract[171]	new[171]	_	_
27-13	3665-3667	to	abstract[171]	new[171]	_	_
27-14	3668-3673	newly	abstract[171]|substance[172]	new[171]|giv[172]	coref	28-6[186_172]
27-15	3674-3682	acquired	abstract[171]|substance[172]	new[171]|giv[172]	_	_
27-16	3683-3694	prodigiosin	abstract[171]|substance[172]	new[171]|giv[172]	_	_
27-17	3695-3703	produced	_	_	_	_
27-18	3704-3706	by	_	_	_	_
27-19	3707-3708	a	abstract[173]	new[173]	_	_
27-20	3709-3714	small	abstract[173]	new[173]	_	_
27-21	3715-3721	number	abstract[173]	new[173]	_	_
27-22	3722-3724	of	abstract[173]	new[173]	_	_
27-23	3725-3739	microorganisms	abstract[173]|abstract	new[173]|new	_	_
27-24	3740-3741	,	abstract[173]	new[173]	_	_
27-25	3742-3751	including	abstract[173]	new[173]	_	_
27-26	3752-3760	Serratia	abstract[173]|place[175]	new[173]|new[175]	_	_
27-27	3761-3771	marcescens	abstract[173]|place[175]	new[173]|new[175]	_	_
27-28	3772-3775	and	abstract[173]	new[173]	_	_
27-29	3776-3781	other	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-30	3782-3790	bacteria	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-31	3791-3792	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-32	3793-3797	such	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-33	3798-3800	as	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-34	3801-3813	Streptomyces	abstract[173]|animal[176]|abstract	new[173]|new[176]|new	_	_
27-35	3814-3827	griseoviridis	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-36	3828-3829	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-37	3830-3838	Serratia	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-38	3839-3843	spp.	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-39	3844-3845	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-40	3846-3864	Zooshikellarubidus	abstract[173]|animal[176]|animal	new[173]|new[176]|new	_	_
27-41	3865-3866	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-42	3867-3873	Vibrio	abstract[173]|animal[176]|person|plant[180]	new[173]|new[176]|new|new[180]	_	_
27-43	3874-3876	sp	abstract[173]|animal[176]|plant[180]	new[173]|new[176]|new[180]	_	_
27-44	3877-3878	.	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-45	3879-3880	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-46	3881-3894	Actinomycetes	abstract[173]|animal[176]|animal	new[173]|new[176]|new	_	_
27-47	3895-3896	,	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-48	3897-3900	and	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-49	3901-3908	Hahella	abstract[173]|animal[176]|substance	new[173]|new[176]|new	_	_
27-50	3909-3919	chejuensis	abstract[173]|animal[176]	new[173]|new[176]	_	_
27-51	3920-3921	.	_	_	_	_

#Text=Research on the mechanism of bacterial origin prodigiosin is very important for clinical application and drug development .
28-1	3922-3930	Research	abstract[183]	new[183]	_	_
28-2	3931-3933	on	abstract[183]	new[183]	_	_
28-3	3934-3937	the	abstract[183]|abstract[184]	new[183]|new[184]	_	_
28-4	3938-3947	mechanism	abstract[183]|abstract[184]	new[183]|new[184]	_	_
28-5	3948-3950	of	abstract[183]|abstract[184]	new[183]|new[184]	_	_
28-6	3951-3960	bacterial	abstract[183]|abstract[184]|substance[186]	new[183]|new[184]|giv[186]	coref	29-22[0_186]
28-7	3961-3967	origin	abstract[183]|abstract[184]|abstract|substance[186]	new[183]|new[184]|new|giv[186]	_	_
28-8	3968-3979	prodigiosin	abstract[183]|abstract[184]|substance[186]	new[183]|new[184]|giv[186]	_	_
28-9	3980-3982	is	_	_	_	_
28-10	3983-3987	very	_	_	_	_
28-11	3988-3997	important	_	_	_	_
28-12	3998-4001	for	_	_	_	_
28-13	4002-4010	clinical	abstract[187]	giv[187]	ana	30-14[0_187]
28-14	4011-4022	application	abstract[187]	giv[187]	_	_
28-15	4023-4026	and	_	_	_	_
28-16	4027-4031	drug	substance|abstract[189]	giv|giv[189]	coref|coref	29-12|29-12
28-17	4032-4043	development	abstract[189]	giv[189]	_	_
28-18	4044-4045	.	_	_	_	_

#Text=In this study , to develop a new type of targeted drug delivery carrier material and investigate the anticancer mechanism of prodigiosin , we first used plCSA-BP as a guide peptide to coat on the DGL vector for cancer-cell-targeted delivery of prodigiosin produced from Serratia marcescens subsp . lawsoniana HDZK-BYSB107 .
29-1	4046-4048	In	_	_	_	_
29-2	4049-4053	this	abstract[190]	new[190]	_	_
29-3	4054-4059	study	abstract[190]	new[190]	_	_
29-4	4060-4061	,	_	_	_	_
29-5	4062-4064	to	_	_	_	_
29-6	4065-4072	develop	_	_	_	_
29-7	4073-4074	a	object[191]	new[191]	_	_
29-8	4075-4078	new	object[191]	new[191]	_	_
29-9	4079-4083	type	object[191]	new[191]	_	_
29-10	4084-4086	of	object[191]	new[191]	_	_
29-11	4087-4095	targeted	object[191]|substance[194]	new[191]|new[194]	_	_
29-12	4096-4100	drug	object[191]|substance|substance[194]	new[191]|giv|new[194]	_	_
29-13	4101-4109	delivery	object[191]|abstract|substance[194]	new[191]|giv|new[194]	_	_
29-14	4110-4117	carrier	object[191]|substance[194]	new[191]|new[194]	_	_
29-15	4118-4126	material	object[191]|substance[194]	new[191]|new[194]	_	_
29-16	4127-4130	and	_	_	_	_
29-17	4131-4142	investigate	_	_	_	_
29-18	4143-4146	the	abstract[195]	new[195]	coref	31-4[215_195]
29-19	4147-4157	anticancer	abstract[195]	new[195]	_	_
29-20	4158-4167	mechanism	abstract[195]	new[195]	_	_
29-21	4168-4170	of	abstract[195]	new[195]	_	_
29-22	4171-4182	prodigiosin	abstract[195]|substance	new[195]|giv	coref	29-42
29-23	4183-4184	,	_	_	_	_
29-24	4185-4187	we	person	acc	ana	30-3
29-25	4188-4193	first	_	_	_	_
29-26	4194-4198	used	_	_	_	_
29-27	4199-4207	plCSA-BP	abstract	giv	_	_
29-28	4208-4210	as	_	_	_	_
29-29	4211-4212	a	_	_	_	_
29-30	4213-4218	guide	_	_	_	_
29-31	4219-4226	peptide	_	_	_	_
29-32	4227-4229	to	_	_	_	_
29-33	4230-4234	coat	_	_	_	_
29-34	4235-4237	on	_	_	_	_
29-35	4238-4241	the	abstract[200]	giv[200]	coref	32-7[220_200]
29-36	4242-4245	DGL	abstract|abstract[200]	giv|giv[200]	_	_
29-37	4246-4252	vector	abstract[200]	giv[200]	_	_
29-38	4253-4256	for	_	_	_	_
29-39	4257-4277	cancer-cell-targeted	abstract[201]	new[201]	coref	32-14[0_201]
29-40	4278-4286	delivery	abstract[201]	new[201]	_	_
29-41	4287-4289	of	abstract[201]	new[201]	_	_
29-42	4290-4301	prodigiosin	abstract[201]|substance	new[201]|giv	_	_
29-43	4302-4310	produced	_	_	_	_
29-44	4311-4315	from	_	_	_	_
29-45	4316-4324	Serratia	_	_	_	_
29-46	4325-4335	marcescens	_	_	_	_
29-47	4336-4341	subsp	_	_	_	_
29-48	4342-4343	.	_	_	_	_
29-49	4344-4354	lawsoniana	time[203]	new[203]	_	_
29-50	4355-4367	HDZK-BYSB107	time[203]	new[203]	_	_
29-51	4368-4369	.	_	_	_	_

#Text=Then , we tested the binding ability of the newly developed DGL/CSA-PNPs and its anticancer effect in vitro on a JEG3 choriocarcinoma cell line and in vivo on a tumor model , respectively .
30-1	4370-4374	Then	_	_	_	_
30-2	4375-4376	,	_	_	_	_
30-3	4377-4379	we	person	giv	_	_
30-4	4380-4386	tested	_	_	_	_
30-5	4387-4390	the	abstract[205]	new[205]	_	_
30-6	4391-4398	binding	abstract[205]	new[205]	_	_
30-7	4399-4406	ability	abstract[205]	new[205]	_	_
30-8	4407-4409	of	abstract[205]	new[205]	_	_
30-9	4410-4413	the	abstract[205]|abstract[206]	new[205]|new[206]	_	_
30-10	4414-4419	newly	abstract[205]|abstract[206]	new[205]|new[206]	_	_
30-11	4420-4429	developed	abstract[205]|abstract[206]	new[205]|new[206]	_	_
30-12	4430-4442	DGL/CSA-PNPs	abstract[205]|abstract[206]	new[205]|new[206]	_	_
30-13	4443-4446	and	abstract[205]	new[205]	_	_
30-14	4447-4450	its	abstract[205]|abstract|abstract[208]	new[205]|giv|new[208]	coref|coref	31-8[216_208]|31-8[216_208]
30-15	4451-4461	anticancer	abstract[205]|abstract[208]	new[205]|new[208]	_	_
30-16	4462-4468	effect	abstract[205]|abstract[208]	new[205]|new[208]	_	_
30-17	4469-4471	in	abstract[205]|abstract[208]	new[205]|new[208]	_	_
30-18	4472-4477	vitro	abstract[205]|abstract[208]	new[205]|new[208]	_	_
30-19	4478-4480	on	abstract[205]|abstract[208]	new[205]|new[208]	_	_
30-20	4481-4482	a	abstract[205]|abstract[208]|object[212]	new[205]|new[208]|new[212]	_	_
30-21	4483-4487	JEG3	abstract[205]|abstract[208]|abstract|object[212]	new[205]|new[208]|new|new[212]	_	_
30-22	4488-4503	choriocarcinoma	abstract[205]|abstract[208]|abstract|object[212]	new[205]|new[208]|giv|new[212]	_	_
30-23	4504-4508	cell	abstract[205]|abstract[208]|object|object[212]	new[205]|new[208]|giv|new[212]	_	_
30-24	4509-4513	line	abstract[205]|abstract[208]|object[212]	new[205]|new[208]|new[212]	_	_
30-25	4514-4517	and	_	_	_	_
30-26	4518-4520	in	_	_	_	_
30-27	4521-4525	vivo	_	_	_	_
30-28	4526-4528	on	_	_	_	_
30-29	4529-4530	a	abstract[214]	new[214]	_	_
30-30	4531-4536	tumor	abstract|abstract[214]	giv|new[214]	_	_
30-31	4537-4542	model	abstract[214]	new[214]	_	_
30-32	4543-4544	,	_	_	_	_
30-33	4545-4557	respectively	_	_	_	_
30-34	4558-4559	.	_	_	_	_

#Text=In addition , the mechanism responsible for the anticancer effect of targeted nano-prodigiosin was also investigated .
31-1	4560-4562	In	_	_	_	_
31-2	4563-4571	addition	_	_	_	_
31-3	4572-4573	,	_	_	_	_
31-4	4574-4577	the	abstract[215]	giv[215]	_	_
31-5	4578-4587	mechanism	abstract[215]	giv[215]	_	_
31-6	4588-4599	responsible	abstract[215]	giv[215]	_	_
31-7	4600-4603	for	_	_	_	_
31-8	4604-4607	the	abstract[216]	giv[216]	_	_
31-9	4608-4618	anticancer	abstract[216]	giv[216]	_	_
31-10	4619-4625	effect	abstract[216]	giv[216]	_	_
31-11	4626-4628	of	abstract[216]	giv[216]	_	_
31-12	4629-4637	targeted	abstract[216]|object[217]	giv[216]|new[217]	_	_
31-13	4638-4654	nano-prodigiosin	abstract[216]|object[217]	giv[216]|new[217]	_	_
31-14	4655-4658	was	_	_	_	_
31-15	4659-4663	also	_	_	_	_
31-16	4664-4676	investigated	_	_	_	_
31-17	4677-4678	.	_	_	_	_

#Text=Overall , these findings suggested that the DGL/CSA vector is an excellent cancer-specific-drug delivery carrier , which has great potential as a novel delivery system for the treatment of cancer .
32-1	4679-4686	Overall	_	_	_	_
32-2	4687-4688	,	_	_	_	_
32-3	4689-4694	these	abstract[218]	new[218]	_	_
32-4	4695-4703	findings	abstract[218]	new[218]	_	_
32-5	4704-4713	suggested	_	_	_	_
32-6	4714-4718	that	_	_	_	_
32-7	4719-4722	the	organization[220]	giv[220]	coref	32-11[222_220]
32-8	4723-4730	DGL/CSA	organization|organization[220]	new|giv[220]	_	_
32-9	4731-4737	vector	organization[220]	giv[220]	_	_
32-10	4738-4740	is	_	_	_	_
32-11	4741-4743	an	organization[222]	giv[222]	_	_
32-12	4744-4753	excellent	organization[222]	giv[222]	_	_
32-13	4754-4774	cancer-specific-drug	organization[222]	giv[222]	_	_
32-14	4775-4783	delivery	abstract|organization[222]	giv|giv[222]	coref	32-24
32-15	4784-4791	carrier	organization[222]	giv[222]	_	_
32-16	4792-4793	,	_	_	_	_
32-17	4794-4799	which	_	_	_	_
32-18	4800-4803	has	_	_	_	_
32-19	4804-4809	great	abstract[223]	new[223]	_	_
32-20	4810-4819	potential	abstract[223]	new[223]	_	_
32-21	4820-4822	as	_	_	_	_
32-22	4823-4824	a	_	_	_	_
32-23	4825-4830	novel	_	_	_	_
32-24	4831-4839	delivery	abstract	giv	_	_
32-25	4840-4846	system	_	_	_	_
32-26	4847-4850	for	_	_	_	_
32-27	4851-4854	the	event[225]	new[225]	_	_
32-28	4855-4864	treatment	event[225]	new[225]	_	_
32-29	4865-4867	of	event[225]	new[225]	_	_
32-30	4868-4874	cancer	event[225]|abstract	new[225]|giv	_	_
32-31	4875-4876	.	_	_	_	_
